Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | LCK | P06239 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | PTPRC | P08575 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22322758 | 0.74 | KMT2A (0.38) | RAB9AMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL18383188 | 0.72 | ALDH1A1 (0.43) | L3MBTL1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL24007634 | 0.71 | KDM4E (0.44) | L3MBTL1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL17323697 | 0.69 | KDM4E (0.39) | L3MBTL1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL29565434 | 0.69 | KDM4E (0.39) | L3MBTL1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL18260522 | 0.69 | KDM4E (0.39) | L3MBTL1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL24007902 | 0.68 | KDM4E (0.41) | L3MBTL1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL13827683 | 0.67 | HTT (0.42) | L3MBTL1RAB9AKDM4EALDH1A1HPGD | |
| SCHEMBL16856891 | 0.67 | KDM4E (0.38) | L3MBTL1RAB9AMEN1KMT2AKDM4E | |
| SCHEMBL29565827 | 0.67 | KDM4E (0.38) | L3MBTL1RAB9AMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2023-08-24 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | AJAX THERAPEUTICS, INC. (US) | 2023-07-04 | — | — | US | disclosed |
| WO-2023009712-A1 | HETEROARYLOXY THIAZOLO AZINES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-02-02 | — | — | WO | disclosed |
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. | 2022-12-29 | — | — | US | disclosed |
| WO-2022140527-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-113912617-A | Substituted tricycles and methods of use | 艾伯维公司 | 2022-01-11 | — | — | CN | disclosed |
| WO-2021226261-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2021-11-11 | — | — | WO | disclosed |
| CN-108349930-B | Substituted tricycles and methods of use | 艾伯维公司 | 2021-10-29 | — | — | CN | disclosed |
| US-20190135827-A1 | Substituted Tricyclics and Method of Use | ABBVIE SARL (LU) | 2019-05-09 | — | — | US | disclosed |
| EP-3322697-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | Abbvie S.a.r.l. (LU) | 2018-05-23 | — | — | EP | disclosed |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | ABBVIE S.Á.R.L. (LU) | 2018-02-08 | — | — | US | disclosed |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | ABBVIE S.Á.R.L. (LU) | 2018-02-08 | — | — | US | disclosed |
| US-9840513-B2 | Substituted tricyclics and method of use | ABBVIE S.Á.R.L. (LU) | 2017-12-12 | — | — | US | disclosed |
| US-9840513-B2 | Substituted tricyclics and method of use | ABBVIE S.Á.R.L. (LU) | 2017-12-12 | — | — | US | disclosed |
| US-20170015675-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-01-19 | — | — | US | disclosed |
| US-20170015675-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | ABBVIE OVERSEAS S.Á.R.L. (LU) | 2017-01-19 | — | — | US | disclosed |
| WO-2017009804-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-01-19 | — | — | WO | disclosed |
| WO-2017009804-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | ABBVIE S.Á.R.L. (LU) | 2017-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411403-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | L3MBTL1 1749/4885RAB9A 3570/4885MEN1 3963/4885 |
| US-20170015675-A1 | SUBSTITUTED TRICYCLICS AND METHOD OF USE | CFTR, F12, CHRM2 | L3MBTL1 4344/4885RAB9A 2081/4885MEN1 2541/4885 |
| US-20230265075-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | L3MBTL1 1749/4885RAB9A 3570/4885MEN1 3963/4885 |
| US-20190135827-A1 | Substituted Tricyclics and Method of Use | CFTR, F12, CHRM2 | L3MBTL1 4344/4885RAB9A 2081/4885MEN1 2541/4885 |
| US-20180037587-A1 | Substituted Tricyclics and Method of Use | CFTR, F12, CHRM2 | L3MBTL1 4344/4885RAB9A 2081/4885MEN1 2541/4885 |
| US-11691963-B2 | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors | JAK2, JAK3, STAT5B | L3MBTL1 1749/4885RAB9A 3570/4885MEN1 3963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.